Samyang Holdings strives to
protect the health of all humankind.

We are committed to ceaseless R&D and investment to offer a healthy lifestyle to human health worldwide and emerge as a biopharmaceutical company that leads innovation across the globe.


A global biopharmaceutical company
that is continuously growing
with exceptional technological prowess

We supply and develop medical devices and pharmaceutical products in various areas of medical treatment, including medical devices (MD) that utilize cutting-edge biodegradable materials, incrementally modified drugs and gene therapeutics, using unique and proprietary drug delivery systems (DDS) that will lead the future of medicine.


We are committed to becoming
a biopharmaceutical company
with innovative R&D capabilities.

Welcome to our website.
I would like to first extend my sincere gratitude to our customers and partners for their unwavering trust and affection towards Samyang Holdings

Samyang Biopharmaceuticals Corporation began as the pharmaceutical business of Samyang Corporation back in 1995. Later it was split off from Samyang Corporation in 2011 and established as Samyang Biopharm, which was followed by a merger with Samyang Holdings, the holding company, in 2021 with the aim to improve corporate value in the mid and long-term and turn it into a global biopharmaceutical company.

To fulfill the vision of "Healthcare value creator who improves the quality of life for patients," we are focusing our resources on the areas of medical devices, pharmaceutical products and gene therapeutics.

In the medical device (MD) area, we developed and commercialized polymer-material-based biodegradable sutures, which we are supplying in the global market, while in the pharmaceutical product area, we developed and produced cytotoxic anti-cancer drugs for treating solid cancer and blood cancer to improve the treatment and survival rate of cancer patients.

Our research focus in Gene Therapeutics is advancing drug delivery technology and exploring novel genetic platforms with the aim to develop innovative therapeutics and vaccines.

We moved our R&D Center and division to Samyang Discovery Center located in Pangyo Techno Valley in 2016, and established Samyang Biopharm USA Inc. in Boston (Cambridge) in 2018 as a global networking hub for open innovation.

Our overseas production plant, Samyang Biopharm Hungary was opened in 2022, which is expected to further expand our business in the global medical device market.

Samyang Biopharmaceuticals Corporation will focus our R&D resources and implement global strategies to thrive as a global pharmaceutical company with innovative R&D capabilities.
Thank you.

Lee Young-Joon

Head of Samyang Holdings biopharmaceutical division

Business Sites

  • Headquarters

    Samyang Discovery Center

    295, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea; Postcode13488



  • R&D Center

    Biopharmaceuticals R&D Center

    295, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea; Postcode13488



  • Plant

    MD Plant

    55, Munpyeongseo-ro 18beon-gil, Daedeok-gu, Daejeon, Korea; Postcode 34302



  • Plant

    Gongju Plant

    11-27, Tancheonsaneopdanji-gil, Tancheon-myeon, Gongju-si, Chungcheongnam-do, Korea; Postcode 32610



  • Plant

    Pharmaceuticals Plant

    79, Sinildong-ro, Daedeok-gu, Daejeon, Korea; Postcode 34324



  • Overseas Subsidiary

    Samyang Biopharm USA

    200 One Kendall Square, Suite 402 Cambridge, MA 02139



  • Overseas Subsidiary

    Samyang Biopharm Hungary

    Gödöllő, Bláthy Ottó utca 2, 2100




We refuse unauthorized email collection


We refuse the unauthorized collection of the email addresses on this website using email collection programs or other technical devices. Please note that any violation will be subject to criminal penalties in accordance with the Act on Information and Communications Network.

Posted on March 28, 2023

Cookie Popup Close
Manage Cookies

This site uses cookies.
By continuing to browse the site,
you agree to the use of cookies.

Privacy Policy Accept